Roche Holding stock expands Alzheimer's pipeline ahead of CTAD
Published on 11/12/2026 at 11:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRoche builds Alzheimer pipeline
- Roche is starting the Phase II TARBELA-AD trial for the oral NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease.
- CTAD will feature new trontinemab findings, including Brainshuttle AD biomarker and amyloid-clearance results.
- Roche will also present clinical and health-economic information on its Elecsys pTau217 and pTau181 blood tests.
Roche announced on Tuesday, November 10, 2026, that it will present new pharmaceutical and diagnostic information at the Clinical Trials on Alzheimer's Disease congress in Boston from November 16 to 19. The announcement, carried by FinanzNachrichten.de, adds a new clinical program to the group's neuroscience pipeline.
New trial targets neuroinflammation
Roche is initiating TARBELA-AD, a Phase II study of the investigational oral NLRP3 inhibitor RG6434 in patients with early symptomatic Alzheimer's disease. The program targets neuroinflammation, complementing Roche's work on amyloid aggregation and its ongoing trontinemab development.
Chief Medical Officer Levi Garraway said the company was pursuing complementary therapeutic approaches because Alzheimer's disease is biologically complex. The statement frames RG6434 as an additional mechanism rather than a replacement for the existing trontinemab programs.
Trontinemab remains a key catalyst
At CTAD, Roche plans to present updated Phase Ib/IIa Brainshuttle AD findings on trontinemab, including information on amyloid removal, pharmacokinetics, pharmacodynamics and safety. The company will also discuss the Phase III PrevenTRON study in cognitively unimpaired people with Alzheimer's biomarkers who face a high risk of clinical decline. PrevenTRON has begun enrolling participants.
The first trontinemab presentations are scheduled for Monday, November 16, while further sessions on RG6434, diagnostics and study design follow through Thursday, November 19. Investors will therefore receive a sequence of pipeline updates rather than a single data release.
Diagnostics broaden the Alzheimer strategy
Roche will present clinical, health-economic and real-world information on its Elecsys pTau217 and pTau181 blood tests. The presentations will examine the use of blood-based biomarkers in primary and specialist care, including diagnostic accuracy, care pathways and potential effects on healthcare efficiency.
Roche Holding stock traded at 439.05 euros on Lang & Schwarz at 11:15 CET on Thursday, November 12, 2026.
Roche Holding at a glance
- Company: Roche Holding AG
- ISIN: CH1499059983
- WKN: A424UK
- Ticker: RHOA
- Trading venue: Lang & Schwarz
- Price: 439.05 euros at 11:15 CET on November 12, 2026
The Swiss market remains the relevant equity-market context for Roche investors.
Further pipeline updates are expected during CTAD. More news and analyses on Roche Holding stock will follow the company's upcoming presentations.
